

Innovative Medicines for Malaysia

1ST NATIONAL BIO-THERAPEUTICS CONGRESS - PUTTING PATIENT FIRST

22 NOVEMBER 2014

The rising costs in healthcare – Can Biosimilars help?

Dr. Paul Cornes





Dr Paul Cornes Conflict of interest

- Salary received:
 - United Kingdom National Health Service
- Honoraria received:
 - Roche
 - Janssen
 - Sandoz
 - Lilly
 - European Generics Association
 - Teva
 - Hospira

The rising costs in healthcare - can Biosimilars help?

Dr Paul Cornes, Consultant Oncologist, Bristol Haematology& Oncology Centre

Comparative Outcomes Group



NH

ESO Task Force Advisory Board on Access to Innovative Treatment in Europe

European School of Oncology Piazza Indipendenza, 2 6500 Bellinzona - Switzerland

paul.cornes@yahoo.co.uk



Question

- Is there sufficient money in the health system to afford innovation in medicine?
- please chose your best response:
- 1. No we do not have the budget to introduce innovation
- 2. Unsure
- 3. Yes we have the chance to increase spending on innovative treatments

There is a cost to cancer care

WØRLD

ECONOMIC

FORUM

WORLD

ECONOMIC

FORUM

D


"Think about health spending as not consumption but investment"

David E. Bloom, professor of economics and demography at Harvard

http://www.bloomberg.com/news/2011-06-20/global-rise-in-cancer-cost-300-billion-in-2010-harvard-economist-says.html File:David E. Bloom at the World Economic Forum Summit on the Global Agenda 2008.jpg


Good news for medicine

- Basic cancer science is paying back on its investment
- One medical paper a minute is added to the PubMed US National Library of Medicine




MEDLINE Citation Counts by Year of Publication. Available at http://www.nlm.nih.gov/bsd/medline_cit_counts_yr_pub.html, accessed 2012 Sept 11. Template:2010 - Impact factor of selected medical journals.jpg/credit

Good news for cancer treatment: Cancer survival is improving




Good news for cancer treatment: Cancer survival is improving



Triggle N. Half of cancer sufferers 'live a decade or more'. BBC News April 29th, 2014. http://www.bbc.co.uk/news/health-27194823. April 29th, 2014.


Good news for cancer treatment

- This investment in innovation means that novel targeted biologic approaches now dominate drug development
- It is predicted that 2012 was probably the year where biologic therapy use outnumbered cytotoxic treatments



Timbs O, Sikora K. Cancer in the year 2025. Cancer World. 2004(September-October):12-19. http://www.cancerworld.org/pdf/7556_05_Grand%20Round_12_19.pdf

Good news for cancer treatment: Innovation in cancer drugs



Cornes P. Pictogram created from data in - Savage P. Development and economic trends in cancer therapeutic drugs: Analysis of modern and historical treatment costs compared to the contemporary GDP per capita. J ClinOncol 32, 2014 (suppl; abstr e17535)




Good news for cancer treatment: Survival impact of some targeted therapies

<text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text>	Cancer Disease	Old Model	Old Survival	Personalized Model	Personalized Survival
	Acute promyelocytic leukemia	Chemotherapy	19 months	All trans	>58 months
	Chronic myeloid leukemia	Chemotherapy	6 years	Imatinih	>22 years
	Melanoma	Dacarbazine	<10 months	Vemurafenib	16 months
	Medullary thyroid cancer	Chemotherapy	36 months	Vandetanib	Not reached
	Gastrointestinal stromal tumour	Chemotherapy	12-18 months	Imatinib	Close to 5 years
	Relapsed Hodgkin lymphoma	Chemotherapy	1.2 years	Brentuximab vedotin	22.4 months

data from Munoz, J.et al (2012) Targeted therapy in rare cancers—adopting the orphans Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.160. Table from The Value of Medical Innovation. http://valueofinnovation.org/a-world-free-from-cancer/#ref3, Accessed April 29, 2014

Good news for cancer treatment



The costly war on cancer. The Economist. 2011 May 26. http://www.economist.com/node/18743951



Bad news for cancer



Delivering affordable cancer care in high-income countries


Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, John Zalcberg, Neal J Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, Ian F Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J Gordon McVie, Arnie D Purushotham, Peter Naredi, Alexander Eggermont, Murray F Brennan, Michael L Steinberg, Mark De Ridder, Susan A McCloskey, Dirk Verellen, Terence Roberts, Guy Storme, Rodney J Hicks, Peter J Ell, Bradford R Hirsch, David P Carbone, Kevin A Schulman, Paul Catchpole, David Taylor, Jan Geissler, Nancy G Brinker, David Meltzer, David Kerr, Matti Aapro

Bad news for cancer treatment

 There will be more cancer to treat as the population ages

Expected rise in 20 years

- http://info.cancerresearchuk.org/ news/archive/pressrelease/ 2011-10-28-NHS-burden-as-cancercases-to-jump-by-45-per-cent
- http://www.breakingnews.ie/archives/ 2006/0607/ireland/potentially-fatalcancer-cases-predicted-to-doubleby-2020-262312.html
- Ibrahim E, et al. Current and future cancer burden in Saudi Arabia: meeting the challenge. Hematol Oncol Stem Cell Ther. 2008 Oct-Dec;1(4):210-5



Bad news for cancer treatment

- Innovative drug development is slow and expensive
- From 5000 10000 compounds in pre-clinical trials:
 - only 0.1% reach clinical trial stage
 - of these, only 10-20% are finally approved
- It takes 15 years from the target discovery to the market at 1.4 Billion Euro / drug
 - Adams CP et al: Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 2006;25:420-428
 - ABPI. Delivering value to the UK: the contribution of the pharmaceutical industry to patients, the NHS and the economy. Updated. http://www.abpi.org.uk/our-work/library/ industry/Pages/310114.aspx. Accessed May 12th, 2014










TIME 13th October, 2008

ASCO 2009 Meeting emphasis: individualised care and cost-effectiveness

USA Medical insurance costs are rising faster than earnings and general inflation



Cost of USA cancer care 1963 to 2004

Cancer treatment spending, in billions

\$72.1

US\$

\$27.5



\$13.1


Medicaid expenditures (\$ billions) for outpatient prescription drugs

US\$

In 2003, Medicaid spent \$33.7 billion on drugs (19% of national spending for drugs and more than 10% of the Medicaid budget)

State Medicaid Outpatient Prescription Drug Policies: Findings from a National Survey, 2005 Update. http://kaiserfamilyfoundation.files.wordpress.com/2013/01/state-medicaid-outpatient-prescription-drug-policies-findings-from-a-national-survey-2005-updatereport.pdf. Accessed Nov 22, 2014


Planning for the future: what will happen to costs?



USA Office of Management and Budget. www.whitehouse.gov/omb


The world spends more each year for cancer treatment

Global spend on oncology drugs: projected for 2010-12




Billions of US Dollars

Innovation is expensive




Kaitlin KI. Deconstructing the drug development process: the new face of innovation. ClinPharmacol& Therapeutics. 2013. Doctors say cancer drug costs are too high. http://medicalxpress.com/news/2013-04-doctors-cancer-drug-high.html. Cited 21/06/2013

Timeline of novel cancer drug approval



Carin A Uyl-de Groot et al. The Economics of Improved Cancer Survival Rates: Better Outcomes, Higher Costs. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):283-292



Association of novel drugs and cancer mortality


Carin A Uyl-de Groot et al. The Economics of Improved Cancer Survival Rates: Better Outcomes, Higher Costs. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):283-292

Association of novel drugs and cancer mortality

Estimated - new medicines have accounted for 50-60% of the increase in cancer survival rates since 1975

Lichtenberg Fr. The Expanding Pharmaceutical Arsenal in the War on Cancer. National Bureau of Economic research Working Paper No. 10328. February 2004.

Cost of cancer drugs by year of approval



Limits on Medicare's ability to control rising spending on cancer drugs

Bach P. N Engl J Med 2009; 360:626-633

What are policy-makers trying to do?


Health Care Will Health Costs Bankrupt America? 02.23.11, 06:00 PM EST Forbes Magazine dated March 14, 2011

What kept going up even in the depths of the worst recession since the 1930s? Health spending.

A forbes.com conversation with Robert Langreth, Avik Roy, David Whelan, Matthew Herper--and our audience.


What kept going up even in the depths of the worst recession since the 1930s? Health spending. It rose 4% in 2009 to an alltime record of 17.6% of gross domestic product. We are far above every other nation in health spending but don't have the longevity to show for it. Health costs are by far the biggest threat to the nation's fiscal health in the long run.

Health care costs are increasing at an annual rate of 7% a year, which if sustained will bankrupt Medicare in nine years and increase the nation's overall annual health care tab to \$4 trillion in 10 years.



Langreth R. Will Health Costs Bankrupt America?. Forbes. http://www.forbes.com/forbes/2011/0314/health-care-recession-expenditure-bankrupt-america.html. Callahan D. Health care costs and medical technology. http://www.thehastingscenter.org/uploadedFiles/Publications/Briefing_Book/health%20care%20costs%20chapter.pdf. Accessed May 7th, 2014

Medical Cost Inflation puts health services at jeopardy



Walsh K. Biosimilars' utilization and the role payers do play in driving uptake in Europe: an industry perspective. Biosimilar Medicines 11th EGA International Symposium, April 2013. Accessed 5th March, 2014

There is no evidence that spending more will consistently improve health

ACP American College of Physicians Internal medicine Doctors for Acults ⁸											
ESTABLISHED IN 1927 BY THE AMERICAN COLLEGE OF PHYSICIANS											
Home Current Issue All Is	sues Online F	First Colle	ections l	n the Clinic	Journal Club	CME					
1 January 2013, Vol 158, No. 1>											
🔤 Email 🧟 Share 🌓 Get Citation 🔳 Slideset (.ppt)											
Reviews 1 January 2013											
The Association Between Health Care Quality and Cost: A Systematic Review Peter S. Hussey, PhD; Samuel Wertheimer, MPH; and Ateev Mehrotra, MD, MPH [+] Article and Author Information Ann Intern Med. 1 January 2013;158(1):27-34 Text Size: A A A											
Article Figures Tables	References	Comments									
Background: Although there is broad policy consensus that both cost containment and quality improvement are critical, the association between costs and quality is poorly understood.											
Purpose: To systematically review evidence of the association between health care quality and cost.											
Data Sources: Electronic literature search of PubMed, EconLit, and EMBASE databases for U.Sbased studies published between 1990 and 2012.											
Study Selection: Title, abstract, and full-text review to identify relevant studies.											

Hussey PS et al. The Association Between Health Care Quality and Cost: A. Ann Intern Med. 1 January 2013;158(1):27-34

There is also no evidence that simple budget cuts will consistently improve health



Focus care to where it helps us live longer and live better



"Estimates suggest that as much as \$700 billion a year in health care costs do not improve health outcomes

They occur because we pay for more care rather than better care"

- Peter Orszag, director of the White House Office of Management and Budget, May 2009 interview with NPR
 - http://www.factsforhealthcare.com/whitepaper/HealthcareWaste.pdf

Education to promote cost-effective care

"billions of euros are wasted, say researchers, because doctors prescribe branded drugs when a generic equivalent is just as good"






DrugWatch

No-name heroes can save Europe billions

🔶 Anna Wagstaff

USA – annual savings from generics in billions USD



Generic Drugs Saved Consumers \$1 Trillion

Consumer Health World - 03 August 2012




nearly \$1 billion of savings every other day.

Consumers saved more than \$1 trillion over the last decade — and \$193 billion in 2011 alone — through their use of generic drugs, according to a new report published by Generic Pharmaceutical Association (GPhA), an industry trade organization.

Using data compiled by IMS Institute for Healthcare Informatics, the Generic Drugs Cost Savings Study reveals that the use of cheaper generic versions of expensive brand-name prescription drugs results in


http://americannewsreport.com/generic-drugs-saved-consumers-1-trillion-8815263 Wyatt E: Justices to take up generic drug case. New York Times, December 8, 2012:B1

1 trillion dollars in 100 dollar notes looks like




http://www.kiplinger.com/article/business/T043-C000-S001-14-ways-to-spend-1-trillion.html Cited 1 July 2013 http://americandigest.org/mt-archives/5minute_arguments/the_awesome_awfulness_of.php. Cited 1 July 2013

Speed of uptake of generics differs by country within the EU




Sheppard A. Generic Medicines: Essential contributors to the long-term health of society. IMS HEALTH, London, UK

Access to innovative drugs differs by country within the EU




Biosimilar medicines

Time to consider biosimilar use is now – the number and value of biologic drugs set to lose patent protection per year to 2015 suggests rapid savings may be gained to reinvest in better care



Sellinger K-H, Wessel R, Biosimilars in an Individualized Therapeutics World – The Challenge in Oncology in Life Science in the Capital Market – Biosimilars, Deutsche VereinigungfürFinanzanalyse und Asset Management. Page 55. Accessed at http://www.dvfa.de/files/die_dvfa/publikationen fachbuecher/application/pdf/dvfa biosimilars 2010.pdf, Jan 21, 2013.

Generics bring treatments into reimbursement that might otherwise be unaffordable




 Shrank WH, The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money. Health Aff (Millwood). 2011 Jul;30(7):1351-7

Cost and access: A survey of Oncologists - USA




- Even in the wealthiest countries there are barriers to accessing the best treatment
- A third of US Oncologists would offer more trastuzumab to breast cancer patients if a lower cost biosimilar was available!
 - Lammers, PE et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets. J ClinOncol 32:5s, 2014 (suppl; abstr 610)



Lammers, PE et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets. J ClinOncol 32:5s, 2014 (suppl; abstr 610)

Savings from biosimilars - Sweden

- Skane University Hospital in Sweden
- Annual saving of €650,000 (6 million SEK)
- From Switching to biosimilar Human Growth Hormone Omnitrope from the original biologic, Somatropin





With no loss of efficacy



With no no serious or unexpected adverse drug reactions



Carl-Erik Flodmark et al. Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden. BiolTher (2013) 3:35–43. DOI 10.1007/s13554-013-0011-z

Savings from biosimilars - UK

- University College London Hospitals NHS Trust also indicate the substantial cost savings possible when switching all patients in a single center from originator rhGH to biosimilarrhGH, with annual savings estimated as in excess of £200,000 / Euro 240,000
 - Thakrar K, Bodalia P, Grosso A. Assessing the efficacy and safety of Omnitrope. Br J Clin Pharm. 2010;2:298–301




Savings from biosimilars - London

- Savings from biosimilar G-CSF switch in London
- G-CSF purchasing cost £3.3 million per year in 2010

£2 million saving from biosimilar switch predicted by 2012

 Antony Grosso, London Procurement Programme, September 2012, quoted in PereGascón et al. Support Care Cancer. 2013; 21: 2925–2932. Published online 2013 August 1. doi: 10.1007/s00520-013-1911-7



Data from UK indicates biosimilars expand access to G-CSF



UK G-CSF volume growth

Percent change vs. previous year


Sept 2008 Biosimilar G-CSF approved

2007 2008 2009 2010

Gascón P et al. Support Care Cancer. 2013; 21: 2925–2932. Published online 2013 August 1. doi: 10.1007/s00520-013-1911-7


Data from UK indicates biosimilars expand access to G-CSF






Gascón P et al. Support Care Cancer. 2013; 21: 2925–2932. Published online 2013 August 1. doi: 10.1007/s00520-013-1911-7. McCamish M et al. The State of the Art in the Development of Biosimilars. Clinical Pharmacology & Therapeutics (2012); 91 3, 405–417. doi:10.1038/clpt.2011.343

Biosimilars improve the standard of care



Walsh K. Biosimilars' utilization and the role payers do play in driving uptake in Europe: an industry perspective. Biosimilar Medicines 11th EGA International Symposium, April 2013. Accessed 5th March, 2014


Biosimilars bring treatments into reimbursement that might otherwise be unaffordable



- Trends in use of white cell growth factors G-CSF before and after biosimilar introduction in the EU
 - IMS Health. Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape. December 2011. http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_ Whitepaper.pdf

Biosimilars improve the standard of care

% of G-CSF as biosimilarsvsNeupogen in Europe, Feb 2013



Source: IMS MIDAS, Feb 2013, quoted in - Walsh K. Biosimilars' utilization and the role payers do play in driving uptake in Europe: an industry perspective. Biosimilar Medicines 11th EGA International Symposium, April 2013. Accessed 5th March, 2014

There is no doubt: even in rich nations -Savings drive increased access to treatment !

 Savings from biosimilar G-CSF switch in Southern Health Care region in Sweden (population 1.7 million)

Five-fold increase in daily G-CSF usage

But still net savings of €2 million

This represents a saving of 4–5% of the total drug budget




Gascón P et al. Support Care Cancer. 2013; 21: 2925–2932. Published online 2013 August 1. doi: 10.1007/s00520-013-1911-7

Cost saving steps with expensive drugs can compromise outcomes

 Prescription data of statutory health insurance members in Germany with G-CSF prescriptions between January 2008 and July 2010 were evaluated (originator filgrastim, n = 8726; biosimilarfilgrastim, n = 4240)

- Hadji et al. Int J ClinPharmacolTher. 2012;50:281-9.



Duration of G-CSF use may affect the quality of care

Incidence of febrile neutropenia in patients receiving secondary prophylaxis

20			Seven or more days of filgrastim leads to better outcomes
15 t			
Percent 01			65% risk reduction
5			Suggests a more affordable drug could
0	<7 days of NEUPOGEN (Mean = 4.7 days)	≥ 7 days of NEUPOGEN (Mean = 10.1 days)	again improve the quality of care

Biosimilar use is increasing

Estimated biosimilar market potential: 2009 value of products whose patents expected to expire between 2009-2019. In absolute value



Rovira J et al, for the European Commission (Directorate-General for Enterprise and Industry) - The impact of biosimilars' entry in the EU market. http://ec.europa.eu/enterprise/sectors/healt hcare/files/docs/biosimilars_market_01201 1_en.pdf

Estonia	9,4
Finland	207,9
France	3.432,5
Germany	3.200,5
Greece	279,8
Hungary	195,2
Ireland	193,9
Italy	1.912,6
Latvia	17,6
Lithuania	17,3
Luxembourg	14,7
Netherlands	365
Norway	207,3
Portugal	52,1
Romania	188,4
Slovakia	124,2
Slovenia	49,5
Spain	1.828,0
Sweden	462,0
Switzerland	353.7
UK	1.351,0




- Höer A. Saving money in the European healthcare systems with biosimilars. GaBI Journal 2012;1(3-4):120-6
- Methods: using a sequential approach, we calculated the savings through the use of biosimilars for 8 of the 28 EU nations -France, Germany, Italy, Poland, Romania, Spain, Sweden and UK
- Results:
 - The use of biosimilars is expected to result in overall savings between Euros 11.8 billion and Euros 33.4 billion between 2007 and 2020, with largest savings expected for France, Germany and UK.
 - Biosimilar monoclonal antibodies 1.8 to 20.4 billion Euros
 - Biosimilarerythropoietins
 - Biosimilar GCSF

- 9.4 to 11.2 billion Euros
- 0.7 to 1.8 billion Euros



Potential USA savings from biosimilar use



Shapiro RJ, Singh K, Mukim M. The Potential American Market for Generic Biological Treatments and the Associated Cost Savings, February 2008. http://www.sonecon.com/docs/studies/0208_GenericBiologicsStudy.pdf

The predicted savings from biosimilars makes them a priority for cost-effective care

- Paul Cornes. The economic pressures for biosimilar drug use in cancer medicine. TargOncol (2012) 7 (Suppl 1):S57–S67. DOI 10.1007/s11523-011-0196-3
 - http://ww 23_2011_

Targ Oncol (2012) 7 (DOI 10.1007/s11523-(

PERSPECTIVES

"...generic versions of the top 12 categories of biologic treatments with patent protections that have expired or that are due to expire in the near future could save Americans \$67 billion to \$108 billion over 10 years and \$236 billion to \$378 billion over 20 years."

The economic pressures for biosimilar drug use in cancer medicine

Paul Cornes


There is no consistent model for governments to promote generic &biosimilar medicines

Differing rules & incentives for use of generic medicines across EU markets leads to different market forces

Rules and Incentives			0	•	Ð	0		٢	0	0	0	6			0	
Market Rules	Mandatory price reduction	1	1					1		1	1				1	
	Patient co-pay		1	1			1			1	1	1	1		1	
	Price referencing			\checkmark	1	1	1		1		\checkmark	\checkmark	1	1		
	Pharmacy-level substitution				1	1				1	1		1	1		1
Market Incentives	At the pharmacy				1	1			1	1	1		1	1		1
	With the health insurers						1			1						
	With wholesalers										\checkmark					
	With payers	\checkmark	\checkmark			1										
	Favouring brands							1				1				
	Favouring generics	1		\checkmark			\checkmark		1		\checkmark			1	1	1

Sheppard A. Generic Medicines: Essential contributors to the long-term health of society. IMS. Available - http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf, accessed Jan 21, 2013


Contrasting generic medicines volume penetration in key countries



Sheppard A. Generic Medicines: Essential contributors to the long-term health of society. IMS. Available - http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf, accessed Jan 21, 2013

There is no consistent model for governments to promote generic &biosimilar medicines

lules	and Incentives			
n	Mandatory price reduction			Perhaps the physicians' leadersh is the missing drive
Rub	Patient co-pay	\checkmark		
Market Rules	Price referencing	1		
Σ	Pharmacy-level substitution		\checkmark	
	At the pharmacy		\checkmark	A De
ន	With the health insurers	1		
entiv	With wholesalers			T
Market Incentives	With payers			
	Favouring brands			
	Favouring generics	1	1	



CAN WE AFFORD THE WAR ON CANCER?

Immunotherapy vaccines could extend survival in a handful of cancers. But personalizing treatment, payers argue, is not sustainable. Where should the line be drawn?


BY ED SILVERMAN

wo years ago, the U.S. Food and Drug Administration took a step that some thought would never occur — it approved the sipuleucel-T (Provenge) vaccine for late-stage prostate cancer. The move came after a protracted episode involving allegations of conflicts of interest among a pair of FDA advisory committee members who reviewed the tending a life by 4.1 months is worth the price of Provenge. It has also prompted larger questions about the underlying technology and the need to develop more vaccines.

Provenge is made by culturing a patient's immune cells with a recombinant antigen. The individualized product is then infused back into the patient, activating the immune system to target and attack the cancer. This "immunotherapy" underscores the move toward personalized



Economics – we need both innovation and value to access better cancer treatment



Gottlieb Daimler

Henry Ford




"We understand that we doctors should be and are stewards of the larger society as well as of the patient in our examination room "

Dr. Lowell E. Schnipper,

Chief of Hematology/Oncology Beth Israel Deaconess Medical Center Chairman of ASCO task force on value in cancer care

Pollack A. Cost of Treatment May Influence Doctors. New York Times 2014 April 17. Grateful nation: Lowell E. Schnipper, M.D. http://www.gratefulnation.org/site/PageNavigator/evening_of_gratitude/Evening_of_gratitude_bios. Accessed June 5th, 2014



Strive not to be a success, but rather to be of value

Question

- Is there sufficient money in the health system to afford innovation in medicine?
- please chose your best response:
- 1. No we do not have the budget to introduce innovation
- 2. Unsure
- 3. Yes we have the chance to increase spending on innovative treatments



Innovative Medicines for Malaysia

1ST NATIONAL BIO-THERAPEUTICS CONGRESS - PUTTING PATIENT FIRST

22 NOVEMBER 2014